ECSP056017A - Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep - Google Patents

Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep

Info

Publication number
ECSP056017A
ECSP056017A EC2005006017A ECSP056017A ECSP056017A EC SP056017 A ECSP056017 A EC SP056017A EC 2005006017 A EC2005006017 A EC 2005006017A EC SP056017 A ECSP056017 A EC SP056017A EC SP056017 A ECSP056017 A EC SP056017A
Authority
EC
Ecuador
Prior art keywords
inhibitors
propilcarbamoil
cicloalquil
benzotiazol
propanoic
Prior art date
Application number
EC2005006017A
Other languages
English (en)
Inventor
David Hepworth
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305916A external-priority patent/GB0305916D0/en
Priority claimed from GB0329143A external-priority patent/GB0329143D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP056017A publication Critical patent/ECSP056017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)

Abstract

La invención se refiere a inhibidores de la enzima endopeptidasa neutra (NEP), a sus usos, a procedimientos para la preparación de los mismos, a intermedios usados en la preparación de los mismos y las composiciones que contienen dichos inhibidores. Estos inhibidores tienen utilidad en varias áreas terapéuticas incluyendo el tratamiento de la disfunción sexual masculina y femenina, particularmente de la disfunción sexual femenina (FSD), especialmente cuando la FSD es un trastorno de excitación sexual femenina (FSAD).
EC2005006017A 2003-03-14 2005-09-14 Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep ECSP056017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305916A GB0305916D0 (en) 2003-03-14 2003-03-14 New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en) 2003-12-16 2003-12-16 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
ECSP056017A true ECSP056017A (es) 2006-01-27

Family

ID=32992599

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006017A ECSP056017A (es) 2003-03-14 2005-09-14 Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep

Country Status (25)

Country Link
US (1) US20040180941A1 (es)
EP (1) EP1606272A1 (es)
JP (1) JP3923512B2 (es)
KR (1) KR20050110003A (es)
AP (1) AP2005003393A0 (es)
AR (1) AR043551A1 (es)
AU (1) AU2004220269A1 (es)
BR (1) BRPI0408377A (es)
CA (1) CA2519072A1 (es)
CL (1) CL2004000512A1 (es)
EA (1) EA200501204A1 (es)
EC (1) ECSP056017A (es)
HR (1) HRP20050797A2 (es)
IS (1) IS8003A (es)
MA (1) MA27720A1 (es)
MX (1) MXPA05009788A (es)
NL (1) NL1025709C2 (es)
NO (1) NO20054169L (es)
OA (1) OA13039A (es)
PA (1) PA8597401A1 (es)
PE (1) PE20050310A1 (es)
TN (1) TNSN05227A1 (es)
TW (1) TW200504038A (es)
UY (1) UY28226A1 (es)
WO (1) WO2004080985A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024241A1 (en) * 2004-08-02 2006-02-02 Bebaas, Inc. Vitamin B12 compositions
WO2006027680A1 (en) * 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
JP5230595B2 (ja) * 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
KR101177866B1 (ko) 2011-03-24 2012-08-28 주식회사 케이엠더블유 케이블 접속 장치
JP2021527875A (ja) * 2018-06-14 2021-10-14 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ Ｃｇｍｐ特異的ホスホジエステラーゼ５阻害剤の薬学的組成物により勃起不全を治療するための方法
CN112997258A (zh) * 2018-06-14 2021-06-18 阿斯利康(英国)有限公司 用cGMP特异性磷酸二酯酶5抑制剂药物组合物治疗勃起功能障碍的方法
WO2020064173A1 (en) 2018-09-25 2020-04-02 Antabio Sas Indane derivatives for use in the treatment of bacterial infection
WO2021091908A1 (en) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
GB202402524D0 (en) * 2024-02-22 2024-04-10 Futura Medical Developments Ltd Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503059A (en) * 1950-04-04 Nxchj
US2599000A (en) * 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
NL175059C (nl) * 1974-02-23 Boehringer Mannheim Gmbh Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) * 1978-04-18 1985-07-26 Acraf Cicloalchiltriazoli
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) * 1985-08-05 1987-02-05 Hoechst Ag Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
CA2189355A1 (en) * 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EE200300469A (et) * 2001-03-28 2004-02-16 Pfizer Inc. N-fenpropüültsüklopentüülasendatud glutaramiidi derivaadid kui NEP inhibiitorid FSAD puhul

Also Published As

Publication number Publication date
CA2519072A1 (en) 2004-09-23
NL1025709C2 (nl) 2005-03-14
CL2004000512A1 (es) 2005-01-21
MXPA05009788A (es) 2005-10-26
AP2005003393A0 (en) 2005-09-30
BRPI0408377A (pt) 2006-03-21
MA27720A1 (fr) 2006-01-02
EA200501204A1 (ru) 2006-06-30
AR043551A1 (es) 2005-08-03
WO2004080985A1 (en) 2004-09-23
AU2004220269A1 (en) 2004-09-23
PA8597401A1 (es) 2005-05-24
JP2006526572A (ja) 2006-11-24
IS8003A (is) 2005-08-29
OA13039A (en) 2006-11-10
NO20054169L (no) 2005-12-07
UY28226A1 (es) 2004-11-08
NO20054169D0 (no) 2005-09-07
US20040180941A1 (en) 2004-09-16
JP3923512B2 (ja) 2007-06-06
KR20050110003A (ko) 2005-11-22
NL1025709A1 (nl) 2004-09-16
TW200504038A (en) 2005-02-01
EP1606272A1 (en) 2005-12-21
PE20050310A1 (es) 2005-05-04
HRP20050797A2 (en) 2006-02-28
TNSN05227A1 (fr) 2007-06-11

Similar Documents

Publication Publication Date Title
UY28226A1 (es) Derivados del ácido 3-(1-(3-(1,3-benzotiazol-6-il)propilcarbamoil)cicloalquil)propanoico como inhibidores de nep
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
EA200970519A1 (ru) Полиморфы сукцината 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2h-пиримидин-1-илметил]-4-фторбензонитрил и способы их применения
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
ATE475655T1 (de) Verfahren zur herstellung von (s)-4- fluormethyldihydrofuran-2-on
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
CL2009000148A1 (es) Acido 2-[1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino] benzoico; proceso para preparar su enantiomero (-) puro; composicion farmaceutica que lo comprende; y su uso en la prevencion y el tratamiento de enfermedades cardiovasculares como trombosis, enfermedades respiratorias y cancer, entre otras.
PE20091834A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona tiofenilo-sustituida como inhibidores de bace-1 y composiciones que los contienen
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
CR8649A (es) Derivados de formamidina para el tratamiento de enfermedades
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
EA201990616A3 (ru) Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
DE602004012418D1 (de) Piperazinderivate und anwendungsverfahren
EA201000041A1 (ru) Липосомная композиция
EP2257161A4 (en) AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
UY28524A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
CR9472A (es) Derivados de aminoacidos
DOP2004000841A (es) Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il)propilcarbamoil]cicloalquil) propanoico como inhibidores de nep
ECSP056106A (es) Compuestos novedosos de acido fosfonico como inhibidores de las serina proteasas
PA8658001A1 (es) Sulfonamido-macrociclos y sus sales, una composicion farmaceutica que comprende estos compuestos, un metodo de preparacion y el uso de los mismos